These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Cryotherapy reduces oral mucositis and febrile episodes in myeloma patients treated with high-dose melphalan and autologous stem cell transplant: a prospective, randomized study. Marchesi F; Tendas A; Giannarelli D; Viggiani C; Gumenyuk S; Renzi D; Franceschini L; Caffarella G; Rizzo M; Palombi F; Pisani F; Romano A; Spadea A; Papa E; Canfora M; Pignatelli A; Cantonetti M; Arcese W; Mengarelli A Bone Marrow Transplant; 2017 Jan; 52(1):154-156. PubMed ID: 27526285 [No Abstract] [Full Text] [Related]
27. A Phase I/II Study of Escalating Doses of Bortezomib in Conjunction with High-Dose Melphalan as a Conditioning Regimen for Salvage Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma. Biran N; Rowley SD; Vesole DH; Zhang S; Donato ML; Richter J; Skarbnik AP; Pecora A; Siegel DS Biol Blood Marrow Transplant; 2016 Dec; 22(12):2165-2171. PubMed ID: 27590107 [TBL] [Abstract][Full Text] [Related]
28. High-dose chemotherapy and autologous stem cell transplantation in multiple myeloma: a single institution experience at All India Institute of Medical Sciences, New Delhi, using non-cryopreserved peripheral blood stem cells. Kayal S; Sharma A; Iqbal S; Tejomurtula T; Cyriac SL; Raina V Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):140-7. PubMed ID: 24342104 [TBL] [Abstract][Full Text] [Related]
29. Combined submyeloablative and myeloablative dose intense melphalan results in satisfactory responses with acceptable toxicity in patients with multiple myeloma. Novitzky N; Thomson J; Thomas V; du Toit C; Mohamed Z; McDonald A Biol Blood Marrow Transplant; 2010 Oct; 16(10):1402-10. PubMed ID: 20385248 [TBL] [Abstract][Full Text] [Related]
30. Melphalan and dexamethasone for patients with multiple myeloma who are not candidates for autologous stem cell transplantation. Sharma A; Lokeshwar N; Raina V; Mohanti BK; Kumar R Natl Med J India; 2007; 20(3):121-4. PubMed ID: 17867615 [TBL] [Abstract][Full Text] [Related]
31. BEAM Conditioning Regimen Has Higher Toxicity Compared With High-Dose Melphalan for Salvage Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma. Veeraputhiran M; Jain T; Deol A; Ayash L; Kim S; Dyson G; Bhutani D; Lum LG; Ratanatharathorn V; Uberti JP; Abidi MH Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):531-5. PubMed ID: 26166312 [TBL] [Abstract][Full Text] [Related]
32. [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature]. Adam Z; Krejcí M; Pour L; Stepánková S; Cermáková Z; Voska L; Teplan V; Krivanová A; Hájek R; Mayer J Vnitr Lek; 2009 Nov; 55(11):1089-96. PubMed ID: 20017442 [TBL] [Abstract][Full Text] [Related]
33. The role of high-dose chemotherapy in the treatment of multiple myeloma: a controversy. Kyle RA Ann Oncol; 2000; 11 Suppl 1():55-8. PubMed ID: 10707780 [TBL] [Abstract][Full Text] [Related]
34. Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib. Aypar E; İzzettin FV; Akı ŞZ; Sancar M; Yeğin ZA; Türköz-Sucak G J Oncol Pharm Pract; 2018 Jun; 24(4):281-289. PubMed ID: 29284356 [TBL] [Abstract][Full Text] [Related]
35. Melphalan 220 mg/m2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma. Moreau P; Milpied N; Mahé B; Juge-Morineau N; Rapp MJ; Bataille R; Harousseau JL Bone Marrow Transplant; 1999 May; 23(10):1003-6. PubMed ID: 10373065 [TBL] [Abstract][Full Text] [Related]
36. Genetic variants in DNA repair pathways are not associated with disease progression among multiple myeloma patients. Thyagarajan B; Arora M; Guan W; Barcelo H; Jackson S; Kumar S; Gertz M Leuk Res; 2013 Nov; 37(11):1527-31. PubMed ID: 24129343 [TBL] [Abstract][Full Text] [Related]
37. Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial. Mai EK; Benner A; Bertsch U; Brossart P; Hänel A; Kunzmann V; Naumann R; Neben K; Egerer G; Ho AD; Hillengass J; Raab MS; Neubauer A; Peyn A; Ko YD; Peter N; Scheid C; Goldschmidt H Br J Haematol; 2016 Jun; 173(5):731-41. PubMed ID: 26990892 [TBL] [Abstract][Full Text] [Related]
39. "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma. Gasparetto C; Gockerman JP; Diehl LF; de Castro CM; Moore JO; Long GD; Horwitz ME; Keogh G; Chute JP; Sullivan KM; Neuwirth R; Davis PH; Sutton LM; Anderson RD; Chao NJ; Rizzieri D Biol Blood Marrow Transplant; 2010 Jan; 16(1):70-7. PubMed ID: 19733251 [TBL] [Abstract][Full Text] [Related]
40. Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma. Rodriguez TE; Hari P; Stiff PJ; Smith SE; Sterrenberg D; Vesole DH Biol Blood Marrow Transplant; 2016 Aug; 22(8):1391-1396. PubMed ID: 27164062 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]